組織診斷市場規模、佔有率和成長分析（按產品類型、技術、疾病類型、檢測方法、最終用戶和地區分類）－2026-2033年產業預測

全球組織診斷市場規模預計在 2024 年達到 56 億美元，從 2025 年的 60.7 億美元成長到 2033 年的 115.7 億美元，在預測期（2026-2033 年）內複合年成長率為 8.4%。

受癌症發病率上升和醫療環境變化的推動，全球組織診斷市場預計將迎來顯著成長。儘管疫情導致資源重新分配，暫時阻礙了診斷檢測，但隨著醫療系統的調整，對精準診斷服務的需求激增。這種需求的復甦凸顯了對各種疾病（尤其是癌症）進行精確監測的迫切需求。此外，隨著解剖病理學和分子病理學的融合日益加深以及液態生物檢體的加速應用，該行業正在經歷重組。對計算病理學的日益重視，強調生物資訊學和分析技術的整合，正在推動創新。過去二十年來，先進儀器的進步徹底改變了病理學家和臨床醫生的能力，進一步推動了臨床病理學領域的擴張。

全球組織診斷市場促進因素

組織診斷市場的關鍵成長要素是慢性疾病（尤其是癌症）發生率的上升。隨著全球癌症發病率的持續成長，對快速、準確的診斷解決方案的需求至關重要，因為早期發現是治療效果的關鍵。免疫組織化學和分子病理學等組織診斷技術的創新使醫療專業人員能夠準確識別腫瘤類型和亞型。對可靠診斷工具日益成長的需求促使醫療機構投資於先進的組織診斷技術。這一趨勢不僅推動了市場成長，也有助於提高癌症患者的醫療服務品質。

限制全球組織診斷市場的因素

全球組織診斷市場面臨的主要挑戰之一是現代診斷技術的高成本。先進的工具和調查方法往往伴隨著沉重的經濟負擔，使得小規模醫院和檢查室難以負擔。設備購置、人員培訓和持續維護等相關費用進一步加劇了這個問題，尤其是在醫療資源有限的地區。因此，高成本阻礙了創新診斷解決方案的普及，尤其是在發展中地區，這限制了患者獲得準確診斷工具的機會，並阻礙了整個組織診斷市場的成長。

全球組織診斷市場趨勢

全球組織診斷市場正經歷著向個人化醫療的重大轉變，其驅動力在於對根據個別患者情況量身定做的精準治療的需求。這一趨勢也受到對能夠識別與各種疾病和腫瘤相關的特定生物標記的先進診斷工具的需求不斷成長的推動。隨著醫療專業人員越來越重視基於基因和分子資訊的個人化治療方案，基因譜分析和分子診斷技術的創新在實現個人化醫療方面發揮關鍵作用。由此產生的對客製化醫療的關注正在推動組織診斷技術的進步，為患者提供更有效、更有針對性的治療選擇。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術分析

全球組織診斷市場規模（按產品類型和複合年成長率分類）（2026-2033 年）

• 消耗品
  • 抗體
  • 成套工具
  • 試劑
  • 探測
• 裝置
  • 玻片染色系統
  • 掃描器
  • 組織處理系統
  • 其他設備

全球組織診斷市場規模（依技術及複合年成長率分類）（2026-2033 年）

• 免疫組織化學
• 原位雜合反應
• 初級染色和特殊染色
• 組織病理學
• 分子病理學
• 數位病理學和工作流程管理
• 特殊染色

全球組織診斷市場規模（按疾病類型和複合年成長率分類）（2026-2033 年）

• 乳癌
• 胃癌
• 淋巴瘤
• 攝護腺癌
• 非小細胞肺癌
• 其他

全球組織診斷市場規模（依診斷方式及複合年成長率分類）（2026-2033 年）

• 臨床
• 製藥/合約研究組織/研究市場

全球組織診斷市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院
• 研究所
• 製藥公司
• 合約研究組織（CRO）
• 其他

全球組織診斷市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific Inc.（USA）
• Siemens Healthineers（Germany）
• Danaher Corporation（USA）
• bioMerieux SA（France）
• QIAGEN NV（Netherlands）
• Becton, Dickinson and Company（BD）（USA）
• Merck KGaA（Germany）
• GE Healthcare（USA）
• BioGenex Laboratories（USA）
• Cell Signaling Technology, Inc.（USA）
• Bio SB（USA）
• DiaGenic ASA（Norway）
• Agilent Technologies（USA）
• Fujirebio Inc.（Japan）
• Tecan Group Ltd.（Switzerland）
• STRATEC SE（Germany）
• Seegene Inc.（South Korea）
• Leica Biosystems（Germany）

結論與建議

Global Tissue Diagnostics Market size was valued at USD 5.60 Billion in 2024 and is poised to grow from USD 6.07 Billion in 2025 to USD 11.57 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global tissue diagnostics market is poised for significant growth, driven by the rising incidence of cancer and an evolving healthcare landscape. The pandemic temporarily hindered diagnostic testing due to resource reallocation, but as healthcare systems adapted, demand for precise diagnostic services surged. This resurgence highlights the urgent need for accurate monitoring of various diseases, particularly cancer. Furthermore, the convergence of anatomic and molecular pathology is reshaping the industry, with liquid biopsies becoming more prevalent. The increasing focus on computational pathology emphasizes the integration of bioinformatics and analytics, fostering innovation. Over two decades, advancements in sophisticated equipment have revolutionized the capabilities of pathologists and clinical practitioners, further propelling the expansion of the clinical pathology domain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tissue Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tissue Diagnostics Market Segments Analysis

Global Tissue Diagnostics Market is segmented by Product Type, Technology, Disease Type, Modality, End-user and region. Based on Product Type, the market is segmented into Consumables and Instruments. Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Anatomic Pathology, Molecular Pathology, Digital Pathology & Workflow Management and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer and Others. Based on Modality, the market is segmented into Clinical and Pharma / CRO / Research Market. Based on End-user, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tissue Diagnostics Market

A significant growth catalyst for the tissue diagnostics market is the rising incidence of chronic diseases, particularly cancer. As global cancer rates continue to escalate, the demand for swift and precise diagnostic solutions becomes crucial, as early detection is key to successful treatment outcomes. Innovations in tissue diagnostics, such as immunohistochemistry and molecular pathology, empower healthcare professionals to accurately identify tumor types and subtypes. The mounting need for reliable diagnostic tools is motivating healthcare providers to invest in advanced tissue diagnostic technologies. This trend not only propels market growth but also enhances the quality of care available to cancer patients.

Restraints in the Global Tissue Diagnostics Market

One significant challenge facing the Global Tissue Diagnostics market is the high cost associated with modern diagnostic techniques. Advanced tools and methodologies often come with substantial financial burdens, making them inaccessible for smaller hospitals and laboratories. The expenses related to equipment acquisition, staff training, and ongoing maintenance further exacerbate this issue, particularly in regions with limited healthcare resources. As a result, the high costs can hinder the adoption of innovative diagnostic solutions, especially in developing areas, which in turn restricts patient access to accurate diagnostic tools and ultimately stifles growth within the overall market for tissue diagnostics.

Market Trends of the Global Tissue Diagnostics Market

The Global Tissue Diagnostics market is experiencing a significant shift towards personalized healthcare, driven by the need for precision therapies that cater to individual patient profiles. This trend is bolstered by the increasing demand for advanced diagnostic tools capable of identifying specific biomarkers linked to various diseases and tumors. As medical professionals increasingly prioritize tailored treatment plans based on genetic and molecular insights, innovations in genetic profiling and molecular diagnostics are playing a crucial role in enabling these personalized approaches. Consequently, this focus on customized healthcare is fueling advancements in tissue diagnostics technology, paving the way for more effective and targeted therapeutic options for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Tissue Diagnostics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Consumables
  • Antibodies
  • Kits
  • Reagents
  • Probes
• Instruments
  • Slide-staining Systems
  • Scanners
  • Tissue-processing Systems
  • Other Instruments

Global Tissue Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunohistochemistry
• In Situ Hybridization
• Primary & Special Staining
• Anatomic Pathology
• Molecular Pathology
• Digital Pathology & Workflow Management
• Special Staining

Global Tissue Diagnostics Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-small Cell Lung Cancer
• Others

Global Tissue Diagnostics Market Size by Modality & CAGR (2026-2033)

• Market Overview
• Clinical
• Pharma / CRO / Research Market

Global Tissue Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Research Laboratories
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Others

Global Tissue Diagnostics Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Disease Type, Modality, End-user)
  • US
  • Canada
• Europe (Product Type, Technology, Disease Type, Modality, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Disease Type, Modality, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Disease Type, Modality, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Disease Type, Modality, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio SB (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaGenic ASA (Norway)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STRATEC SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations